160 related articles for article (PubMed ID: 35960538)
1. Construction of Covalent Bisubstrate Inhibitor of Protein Kinase Reacting with Cysteine Residue at Substrate-Binding Site.
Sõrmus T; Lavogina D; Teearu A; Enkvist E; Uri A; Viht K
J Med Chem; 2022 Aug; 65(16):10975-10991. PubMed ID: 35960538
[TBL] [Abstract][Full Text] [Related]
2. Covalent Proximity Scanning of a Distal Cysteine to Target PI3Kα.
Borsari C; Keles E; McPhail JA; Schaefer A; Sriramaratnam R; Goch W; Schaefer T; De Pascale M; Bal W; Gstaiger M; Burke JE; Wymann MP
J Am Chem Soc; 2022 Apr; 144(14):6326-6342. PubMed ID: 35353516
[TBL] [Abstract][Full Text] [Related]
3. Deactivatable Bisubstrate Inhibitors of Protein Kinases.
Sõrmus T; Lavogina D; Enkvist E; Uri A; Viht K
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235226
[TBL] [Abstract][Full Text] [Related]
4. Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors.
Leproult E; Barluenga S; Moras D; Wurtz JM; Winssinger N
J Med Chem; 2011 Mar; 54(5):1347-55. PubMed ID: 21322567
[TBL] [Abstract][Full Text] [Related]
5. Determining Cysteines Available for Covalent Inhibition Across the Human Kinome.
Zhao Z; Liu Q; Bliven S; Xie L; Bourne PE
J Med Chem; 2017 Apr; 60(7):2879-2889. PubMed ID: 28326775
[TBL] [Abstract][Full Text] [Related]
6. Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance.
Schwartz PA; Kuzmic P; Solowiej J; Bergqvist S; Bolanos B; Almaden C; Nagata A; Ryan K; Feng J; Dalvie D; Kath JC; Xu M; Wani R; Murray BW
Proc Natl Acad Sci U S A; 2014 Jan; 111(1):173-8. PubMed ID: 24347635
[TBL] [Abstract][Full Text] [Related]
7. New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors.
Lamba V; Ghosh I
Curr Pharm Des; 2012; 18(20):2936-45. PubMed ID: 22571662
[TBL] [Abstract][Full Text] [Related]
8. Developing irreversible inhibitors of the protein kinase cysteinome.
Liu Q; Sabnis Y; Zhao Z; Zhang T; Buhrlage SJ; Jones LH; Gray NS
Chem Biol; 2013 Feb; 20(2):146-59. PubMed ID: 23438744
[TBL] [Abstract][Full Text] [Related]
9. Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs).
Roskoski R
Pharmacol Res; 2021 Mar; 165():105422. PubMed ID: 33434619
[TBL] [Abstract][Full Text] [Related]
10. Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with α-Substituent Electrophiles Targeting Cysteine.
Ai Y; Yang Z; Yang Z; Wan S; Huang C; Huang C; Li M; Li Z; Zhang J; Zhang T
J Chem Inf Model; 2023 Jan; 63(2):493-506. PubMed ID: 36632804
[TBL] [Abstract][Full Text] [Related]
11. Irreversible protein kinase inhibitors.
Garuti L; Roberti M; Bottegoni G
Curr Med Chem; 2011; 18(20):2981-94. PubMed ID: 21651479
[TBL] [Abstract][Full Text] [Related]
12. Assessing Lysine and Cysteine Reactivities for Designing Targeted Covalent Kinase Inhibitors.
Liu R; Yue Z; Tsai CC; Shen J
J Am Chem Soc; 2019 Apr; 141(16):6553-6560. PubMed ID: 30945531
[TBL] [Abstract][Full Text] [Related]
13. Diversity of bisubstrate binding modes of adenosine analogue-oligoarginine conjugates in protein kinase a and implications for protein substrate interactions.
Pflug A; Rogozina J; Lavogina D; Enkvist E; Uri A; Engh RA; Bossemeyer D
J Mol Biol; 2010 Oct; 403(1):66-77. PubMed ID: 20732331
[TBL] [Abstract][Full Text] [Related]
14. The Meisenheimer Complex as a Paradigm in Drug Discovery: Reversible Covalent Inhibition through C67 of the ATP Binding Site of PLK1.
Pearson RJ; Blake DG; Mezna M; Fischer PM; Westwood NJ; McInnes C
Cell Chem Biol; 2018 Sep; 25(9):1107-1116.e4. PubMed ID: 30017915
[TBL] [Abstract][Full Text] [Related]
15. Bisubstrate inhibitor approach for targeting mitotic kinase Haspin.
Kestav K; Lavogina D; Raidaru G; Chaikuad A; Knapp S; Uri A
Bioconjug Chem; 2015 Feb; 26(2):225-34. PubMed ID: 25595038
[TBL] [Abstract][Full Text] [Related]
16. Chemical genetic strategy for targeting protein kinases based on covalent complementarity.
Garske AL; Peters U; Cortesi AT; Perez JL; Shokat KM
Proc Natl Acad Sci U S A; 2011 Sep; 108(37):15046-52. PubMed ID: 21852571
[TBL] [Abstract][Full Text] [Related]
17. The Cysteinome of Protein Kinases as a Target in Drug Development.
Chaikuad A; Koch P; Laufer SA; Knapp S
Angew Chem Int Ed Engl; 2018 Apr; 57(16):4372-4385. PubMed ID: 28994500
[TBL] [Abstract][Full Text] [Related]
18. A potent fluorescent ATP-like inhibitor of cAMP-dependent protein kinase.
Wu JC; Chuan H; Wang JH
J Biol Chem; 1989 May; 264(14):7989-93. PubMed ID: 2542258
[TBL] [Abstract][Full Text] [Related]
19. Design, validation and efficacy of bisubstrate inhibitors specifically affecting ecto-CK2 kinase activity.
Cozza G; Zanin S; Sarno S; Costa E; Girardi C; Ribaudo G; Salvi M; Zagotto G; Ruzzene M; Pinna LA
Biochem J; 2015 Nov; 471(3):415-30. PubMed ID: 26349539
[TBL] [Abstract][Full Text] [Related]
20. Mg X ATP2-dependent interaction of the inhibitor protein of the cAMP-dependent protein kinase with the catalytic subunit.
Whitehouse S; Walsh DA
J Biol Chem; 1983 Mar; 258(6):3682-92. PubMed ID: 6219994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
